Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc.verified

ACRS

Price:

$4.32

Market Cap:

$520.97M

Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoi...[Read more]

Industry

Biotechnology

IPO Date

2015-10-06

Stock Exchange

NASDAQ

Ticker

ACRS

The Enterprise Value as of June 2026 (TTM) for Aclaris Therapeutics, Inc. (ACRS) is 494.30M

According to Aclaris Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 494.30M. This represents a change of 69.17% compared to the average of 292.18M of the last 4 quarters.

Aclaris Therapeutics, Inc. (ACRS) Historical Enterprise Value (quarterly & annually)

How has ACRS Enterprise Value performed in the past?

The mean historical Enterprise Value of Aclaris Therapeutics, Inc. over the last ten years is 389.41M. The current 494.30M Enterprise Value has changed 12.59% with respect to the historical average. Over the past ten years (40 quarters), ACRS's Enterprise Value was at its highest in in the March 2021 quarter at 1.24B. The Enterprise Value was at its lowest in in the March 2020 quarter at 488.17K.

Quarterly (TTM)
Annual

Average

389.41M

Median

307.90M

Minimum

33.85M

Maximum

982.53M

Aclaris Therapeutics, Inc. (ACRS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Aclaris Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 493.51%

Maximum Annual Enterprise Value = 982.53M

Minimum Annual Increase = -96.56%

Minimum Annual Enterprise Value = 33.85M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2025351.38M110.25%
2024167.13M393.76%
202333.85M-96.56%
2022982.53M23.09%
2021798.21M201.87%
2020264.42M493.51%
201944.55M-79.44%
2018216.70M-55.25%
2017484.29M-12.11%
2016551.05M12.06%

Aclaris Therapeutics, Inc. (ACRS) Average Enterprise Value

How has ACRS Enterprise Value performed in the past?

The current Enterprise Value of Aclaris Therapeutics, Inc. (ACRS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

184.12M

5-year avg

466.62M

10-year avg

389.41M

Aclaris Therapeutics, Inc. (ACRS) Enterprise Value vs. Peers

How is ACRS’s Enterprise Value compared to its peers?

Aclaris Therapeutics, Inc.’s Enterprise Value is greater than Cabaletta Bio, Inc. (400.61M), greater than Exagen Inc. (96.17M), greater than Editas Medicine, Inc. (193.08M), less than NeoGenomics, Inc. (552.76M), less than Owens & Minor, Inc. (2.09B), greater than Senseonics Holdings, Inc. (313.14M), less than Allogene Therapeutics, Inc. (514.09M), greater than MDxHealth S.A. (93.93M), greater than BioAge Labs, Inc. (441.46M), greater than 908 Devices Inc. (249.62M),

CompanyEnterprise ValueMarket cap
400.61M$490.79M
96.17M$112.83M
193.08M$244.75M
552.76M$290.37M
2.09B$207.07M
313.14M$299.93M
514.09M$463.35M
93.93M$27.85M
441.46M$679.20M
249.62M$312.72M

Build a custom stock screener for Aclaris Therapeutics, Inc. (ACRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aclaris Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aclaris Therapeutics, Inc. (ACRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aclaris Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Aclaris Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Aclaris Therapeutics, Inc. (ACRS)?

What is the 3-year average Enterprise Value for Aclaris Therapeutics, Inc. (ACRS)?

What is the 5-year average Enterprise Value for Aclaris Therapeutics, Inc. (ACRS)?

How does the current Enterprise Value for Aclaris Therapeutics, Inc. (ACRS) compare to its historical average?